Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial.
about
Managing anxiety associated with neurodegenerative disordersA brief history of the development of antidepressant drugs: from monoamines to glutamateExperimental medication treatment approaches for depression.New targets for rapid antidepressant action.Novel Glutamatergic Treatments for Severe Mood Disorders.Failure of memantine to "reverse" quinpirole-induced hypomotility.Synaptic Plasticity, Metaplasticity and Depression.Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders?Issues encountered in recent attempts to develop novel antidepressant agents.Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder.Strategies to mitigate dissociative and psychotomimetic effects of ketamine in the treatment of major depressive episodes: a narrative review.What is the mechanism of Ketamine's rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities.A Meta-Analysis of Memantine for Depression.Antidepressant, anxiolytic and procognitive effects of rivastigmine and donepezil in the chronic mild stress model in rats.The Black Book of Psychotropic Dosing and Monitoring.Addressing the unmet needs of current antidepressants: does neuroscience help or hinder clinical psychopharmacology research?Effect of memantine combination therapy on symptoms in patients with moderate-to-severe depressive disorder: randomized, double-blind, placebo-controlled study.Convergent Mechanisms Underlying Rapid Antidepressant Action.Disinhibition of CA1 pyramidal cells by low-dose ketamine and other antagonists with rapid antidepressant efficacy.
P2860
Q27024451-54350F6A-00BD-48F6-B576-CCFEE08EDD91Q27028050-2F653E51-623B-462F-973C-561FE7B47FC0Q33635577-6993360D-D513-4E34-B7B8-BFED973A3E01Q34507177-BD51309B-CE67-4278-804F-25415A98558BQ36498659-5DB29FE2-F6B0-49CB-A3E5-11E41FF41CF2Q37033976-6EDB49C7-2EBC-4E29-AE43-68946E5D18F7Q37668039-30A65AE0-C32A-4211-BBA9-184D29C099E8Q38254452-AE409860-01C3-459C-A0BC-1D9ECC51FB2CQ38374429-43C71BAD-5EC8-42B1-8B9D-ABECBF463995Q38543238-7B38633E-47A6-4E15-BDEB-1258F8249F53Q38692317-32EC0DAF-CC2E-4685-8EE1-145B8C5060B1Q39006234-840EAB55-2977-4592-A55B-C40EEE0F9975Q39145461-5B1DC1A9-8245-43E9-80AC-FF70BCB84BBDQ39301254-9A144181-B3C8-42B4-8D65-C454A008A32CQ47642128-B53A3994-DE6F-4874-B52A-6DB67DBEEEA4Q47805452-2441F529-5F14-4862-AE52-5BB0706BD6F3Q47889297-9FF6A475-DC52-460D-9D51-0781AB9F72A4Q52667723-D8085D98-B6AD-4BB2-BA0E-7280EA89BBBFQ53838133-BBB6A786-C415-4532-B20D-2F13F39E12EC
P2860
Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antidepressant augmentation us ...... ind, placebo-controlled trial.
@en
Antidepressant augmentation us ...... ind, placebo-controlled trial.
@nl
type
label
Antidepressant augmentation us ...... ind, placebo-controlled trial.
@en
Antidepressant augmentation us ...... ind, placebo-controlled trial.
@nl
prefLabel
Antidepressant augmentation us ...... ind, placebo-controlled trial.
@en
Antidepressant augmentation us ...... ind, placebo-controlled trial.
@nl
P2093
P2860
P356
P1476
Antidepressant augmentation us ...... ind, placebo-controlled trial.
@en
P2093
Anthony J Rothschild
Chelsea S Landolin
Christine M Ulbricht
Eric G Smith
Jayendra K Patel
P2860
P304
P356
10.4088/JCP.12M08252
P577
2013-10-01T00:00:00Z